UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

CCI	UCI	DUL	E	12D
$\mathbf{S}\mathbf{G}$		JUL	J.C.	TOD

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

Syndax Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value (Title of Class of Securities)

87164F105 (CUSIP Number)

Alejandro Moreno c/o Access Industries, Inc. 40 West 57th St., 28th Floor New York, New York 10019 (212) 247-6400

with copies to:

Matthew E. Kaplan Debevoise & Plimpton LLP 919 Third Avenue New York, New York 10022 (212) 909-6000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 25, 2022 (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d-1(e), 13d-1(g), check the following box. \Box

1	NAME OF REPORTING PERSON.						
	Access Industries Holdings LLC						
2			PROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
	(a) □ (l	b) 🗆					
3	SEC USE O	NLY					
4	SOURCE O	F FUN	NDS (SEE INSTRUCTIONS)				
	AF						
5	CHECK IF I	DISCI	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)				
6		IIP OF	R PLACE OF ORGANIZATION				
	State of Dela						
	7 SOLE VOTING POWER						
N	UMBER OF		0 shares				
BE	SHARES NEFICIALLY	8	SHARED VOTING POWER				
	WNED BY		2,603,709 shares				
ъ	EACH	9	SOLE DISPOSITIVE POWER				
	EPORTING PERSON						
	WITH	10	0 shares				
		10	SHARED DISPOSITIVE POWER				
			2,603,709 shares				
11	AGGREGAT	ΓE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	2,603,709 sh	ares					
12			AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
10	DEDCEME	OF CI	ACC DEDDECEMTED DV AMOUNT IN DOM (41).				
13	PERCENT (JF CL	ASS REPRESENTED BY AMOUNT IN ROW (11);				
	4.7%(1)						
14	TYPE OF R	EPOR	TING PERSON (SEE INSTRUCTIONS)				
	OO (Limited	l Liab	ility Company)				

1	NAME OF REPORTING PERSON.						
	AI Life Sciences Investments LLC						
2	CHECK TH	E API	PROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
	(a) □ (l	o) 🗆					
3	SEC USE O	NLY					
4	SOURCE O	E ELIN	NDS (SEE INSTRUCTIONS)				
-	BOOKGE O	1 1 01	(DEE INOTINOCITORO)				
	WC						
5	CHECK IF I	DISCI	LOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)				
6		ID UE	R PLACE OF ORGANIZATION				
J	CITIZLIVOII	01	CLETCE OF ORGANIZATION				
	State of Dela	ware					
	7 SOLE VOTING POWER						
N	UMBER OF		2,603,709 shares				
	SHARES	8	SHARED VOTING POWER				
BE	NEFICIALLY	Ü	SIMILED VOINGTOWER				
C	WNED BY		0 shares				
R	EACH EPORTING	9	SOLE DISPOSITIVE POWER				
1,	PERSON						
	WITH		2,603,709 shares				
		10	SHARED DISPOSITIVE POWER				
			0 shares				
11	AGGREGAT	ΓE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
4.5	2,603,709 sh						
12	CHECK IF T	THE A	AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
13		OF CL	ASS REPRESENTED BY AMOUNT IN ROW (11);				
	4.7%(1)						
14	TYPE OF R	EPOR	TING PERSON (SEE INSTRUCTIONS)				
	OO (Limited	l Liabi	ility Company)				

1	NAME OF REPORTING PERSON.						
	AI LSI-SPV LLC						
2			PROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
	(a) □ (l	o) 🗆					
3	SEC USE O	NLY					
4	SOURCE O	F FUN	NDS (SEE INSTRUCTIONS)				
	AF						
5		DISCI	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)				
6		IIP OF	R PLACE OF ORGANIZATION				
	State of Dela						
	7 SOLE VOTING POWER						
N	UMBER OF		0 shares				
BE	SHARES NEFICIALLY	8	SHARED VOTING POWER				
	WNED BY		2,603,709 shares				
D	EACH EPORTING	9	SOLE DISPOSITIVE POWER				
	PERSON						
	WITH	10	0 shares SHARED DISPOSITIVE POWER				
		10	SHARED DISPOSITIVE POWER				
			2,603,709 shares				
11	AGGREGAT	ΓE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	2,603,709 sh	ares					
12			AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
13		DE CI	ASS REPRESENTED BY AMOUNT IN ROW (11);				
15	LLICLIVI), UL	AUDITED DI TEMODITI IN NOW (11),				
	4.7%(1)						
14	TYPE OF R	EPOR	TING PERSON (SEE INSTRUCTIONS)				
	OO (Limited	l Liabi	ility Company)				

1	NAME OF I	REPO	RTING PERSON.				
	Access Industries Holdings (BVI) L.P.						
2			PROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
	(a) □ (b) □						
3	SEC USE O	NLY					
4	SOURCE O	F FUN	IDS (SEE INSTRUCTIONS)				
	A.E.						
5	AF	NCCI	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)				
5	CHECK IF I	JISCI	COSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO TEMS 2(0) of 2(e)				
6		ID OF	R PLACE OF ORGANIZATION				
U	CITIZENSII	ii Oi	AT EAGE OF ORGANIZATION				
	British Virgi	n Islai	nds				
		7	SOLE VOTING POWER				
	7 SOLE VOING TOWER						
N	UMBER OF		0 shares				
SHARES		8	SHARED VOTING POWER				
	NEFICIALLY						
U	OWNED BY EACH		2,603,709 shares				
R	EACH EPORTING	9	SOLE DISPOSITIVE POWER				
	PERSON						
	WITH		0 shares				
		10	SHARED DISPOSITIVE POWER				
			2,603,709 shares				
11	AGGREGA	IE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	2,603,709 sh	ores					
12			AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
14	CHECK IF	LIIE F	AGGREGATE AMOUNT IN NOW (11) EACEODES CERTAIN STIARES (SEE INSTRUCTIONS)				
13		OF CL	ASS REPRESENTED BY AMOUNT IN ROW (11);				
	4.7%(1)						
14	TYPE OF R	EPOR	TING PERSON (SEE INSTRUCTIONS)				
	PN						

1	NAME OF REPORTING PERSON.					
	Access Industries, LLC					
2	CHECK TH	E API	PROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
	(a) □ (b) [
3	SEC USE O	NLY				
4	SOURCE O	F FUN	NDS (SEE INSTRUCTIONS)			
	AF					
5	CHECK IF I	DISCL	LOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)			
6	_	ID OF	R PLACE OF ORGANIZATION			
U	CITIZEI	11 01	AT EACE OF ORGANIZATION			
	State of Dela	ware				
		7	SOLE VOTING POWER			
N	UMBER OF		0 shares			
DE	SHARES	8	SHARED VOTING POWER			
	NEFICIALLY WNED BY					
C	EACH		2,603,709 shares			
R	EPORTING	9	SOLE DISPOSITIVE POWER			
	PERSON					
	WITH	10	0 shares			
		10	SHARED DISPOSITIVE POWER			
			2,603,709 shares			
11	AGGREGAT	ΈAΝ	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	2,603,709 sh	ares				
12	CHECK IF T	THE A	AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
13	PERCENT C	OF CL	ASS REPRESENTED BY AMOUNT IN ROW (11);			
	4.70/(1)					
1.4		TDOD	TIMO DEDCOM (SEE INSTRUCTIONS)			
14	IYPE OF RI	EPUK	THING PERSON (SEE INSTRUCTIONS)			
	OO (Limited	Liabi	ility Company)			
14			TING PERSON (SEE INSTRUCTIONS) ility Company)			

1	NAME OF REPORTING PERSON.					
	Access Industries Management, LLC					
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)					
	(a) □ (l	o) 🗆				
3	SEC USE O	NII X/				
3	SEC USE U	NLI				
4	SOURCE O	E ELIN	IDS (SEE INSTRUCTIONS)			
7	SOURCE O	1 1 01	(DEE INSTRUCTIONS)			
	AF					
5	CHECK IF I	DISCI	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)			
6	CITIZENSH	IP OF	R PLACE OF ORGANIZATION			
	G					
	State of Dela		COLE MOTING POLITER			
		7	SOLE VOTING POWER			
N	UMBER OF		0 shares			
	SHARES	8	SHARED VOTING POWER			
	NEFICIALLY	Ü	SIRIND VOING FOWER			
C	OWNED BY		2,603,709 shares			
D	EACH EPORTING	9	SOLE DISPOSITIVE POWER			
IX	PERSON					
	WITH		0 shares			
		10	SHARED DISPOSITIVE POWER			
			0.000,700,1			
11	A CCDEC AT	CE AN	2,603,709 shares MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
11	AGGREGA	LE AN	IOUNI BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	2,603,709 sh	ares				
12						
13	PERCENT (F CL	ASS REPRESENTED BY AMOUNT IN ROW (11);			
4.	4.7%(1)	EDGE	TING DEPON (OFF INCTINATIONS)			
14	TYPE OF R	EPOR	TING PERSON (SEE INSTRUCTIONS)			
	OO (Limited	l Liabi	lity Company)			

\cap I	IC.	ID	Nο	871	164	E1	N5

1	NAME OF REPORTING PERSON.					
2	Len Blavatnik					
2		E API 5) □	PROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
	(a) 🗆 (i	<i>)</i> , ப				
3	SEC USE O	NLY				
5	SEC CSE O					
4	SOURCE O	F FUN	IDS (SEE INSTRUCTIONS)			
	AF					
5	CHECK IF I	DISCI	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)			
	CIETZENCI	IID OI	N N A CE OF OD CANUZATION			
6	CITIZENSH	IIP OF	R PLACE OF ORGANIZATION			
	United State	s of A	merica			
	Omica State	7	SOLE VOTING POWER			
		,				
N	UMBER OF		0 shares			
DE	SHARES	8	SHARED VOTING POWER			
	NEFICIALLY WNED BY					
	EACH		2,603,709 shares			
R	EPORTING	9	SOLE DISPOSITIVE POWER			
	PERSON		0 shares			
	WITH	10	SHARED DISPOSITIVE POWER			
		10	SHARED DISPOSITIVE FOWER			
			2,603,709 shares			
11	AGGREGAT	ΓΕ ΑΝ	10UNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	2,603,709 sh					
12	CHECK IF	Γ HE A	AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
13)F CI	ASS REPRESENTED BY AMOUNT IN ROW (11);			
10	I LICCLIAI (). UL	100 101 1001 11 1001 (11),			
	4.7%(1)					
14		EPOR	TING PERSON (SEE INSTRUCTIONS)			
	IN					

⁽¹⁾ All percentages of ownership of the Common Stock by Reporting Persons presented in this Statement are based on 55,012,245 shares of Common Stock outstanding, as of February 25, 2022, as set forth in the Issuer's Form 10-K filed with the Securities and Exchange Commission on March 1, 2022.

Amendment No. 1 to Schedule 13D

This amendment to Schedule 13D is being filed by Access Industries Holdings LLC ("AIH"), AI Life Sciences Investments LLC ("AI Life Sciences"), AI LSI-SPV LLC ("AI LSI"), Access Industries Holdings (BVI) L.P. ("AIH BVI"), Access Industries, LLC ("AI"), Access Industries Management, LLC ("AIM") and Len Blavatnik (collectively, the "Reporting Persons", and each, a "Reporting Person") to report the change in ownership of shares of common stock, \$0.0001 par value per share (the "Common Stock"), of Syndax Pharmaceuticals, Inc. (the "Issuer").

The Schedule 13D (the "Schedule") filed with the Securities and Exchange Commission on May 3, 2021 is hereby amended and supplemented by the Reporting Persons as set forth below in this Amendment No. 1. This amendment is filed by the Reporting Persons in accordance with Rule 13d-2 of the Securities Exchange Act of 1934, as amended, and refers only to information that has materially changed since the filing of the Schedule. The items identified below, or the particular paragraphs of such items which are identified below, are amended as set forth below. Unless otherwise indicated, all capitalized terms used and not defined herein have the respective meanings assigned to them in the Schedule.

Item 5 Interest in Securities of the Issuer

The disclosure in Item 5 is hereby amended and restated in its entirety to read as follows:

(a) and (b) The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of Common Stock (including, but not limited to, footnotes to such information) are incorporated herein by reference.

The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the number of Common Stock as to which each of the persons or entities referenced in Item 2 has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including, but not limited to, footnotes to such information) are incorporated herein by reference.

2,603,709 shares of Common Stock are owned directly by AI Life Sciences and may be deemed to be beneficially owned by AIH, AI LSI, AIH BVI, AI, AIM and Len Blavatnik because (i) AI owns a majority of the membership interests of AIH BVI, (ii) AIM controls AI, AIH, AIH BVI and AI LSI Management LLC (the managing member of AI Life Sciences), (iii) Mr. Blavatnik is the controlling person of AIM, AI and AIH BVI, (iv) AIH BVI controls AIH and (v) AIH controls AI LSI (which holds certain membership interests in AI Life Sciences). Each of the Reporting Persons (other than AI Life Sciences), and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.

- (c) Not applicable.
- (d) Not applicable.
- (e) As of February 25, 2022, each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the shares of Common Stock.

Item 7 Materials to Be Filed as Exhibits

The disclosure in Item 7 is hereby supplemented by adding the following in appropriate numerical order:

Exhibit Description

99.1.1 Joint Filing Agreement, dated as of March 4, 2022.

SIGNATURE

	After reasonable inquiry	and to the best of my	knowledge and belief,	I certify that the	information set forth	in this statement is true,	complete and
COTTE	ect						

Date: March 4, 2022

ACCESS INDUSTRIES HOLDINGS LLC By: Access Industries Management, LLC, its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

AI LIFE SCIENCES INVESTMENTS LLC

By: AI LSI Management, LLC, its Managing Member

By: Access Industries Management, LLC, its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

AI LSI-SPV LLC By: Access Industries Management, LLC, its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

ACCESS INDUSTRIES HOLDINGS (BVI) L.P. By: Access Industries Management, LLC, its General Partner

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

ACCESS INDUSTRIES, LLC By: Access Industries Management, LLC, its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

ACCESS INDUSTRIES MANAGEMENT, LLC /s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

*

Name: Len Blavatnik

By: /s/ Alejandro Moreno

Name: Alejandro Moreno Attorney-in-Fact

^{*} The undersigned, by signing his name hereto, executes this Schedule 13D pursuant to the Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

Joint Filing Agreement

The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

In accordance with Rule 13d-1(k)(1) promulgated under the Securities and Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (and any amendments thereto) with respect to the Common Stock, par value \$0.0001, beneficially owned by each of them, of Syndax Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Delaware. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13D.

[Signature Page Follows]

 $IN\ WITNESS\ WHEREOF, the\ undersigned\ hereby\ execute\ this\ Joint\ Filing\ Agreement\ as\ of\ the\ 4^{th}\ day\ of\ March,\ 2022.$

ACCESS INDUSTRIES HOLDINGS LLC By: Access Industries Management, LLC, its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno
Title: Executive Vice President

AI LIFE SCIENCES INVESTMENTS LLC

By: AI LSI Management, LLC, its Managing Member

By: Access Industries Management, LLC, its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

AI LSI-SPV LLC By: Access Industries Management, LLC, its Manager

/s/ Alejandro Moreno Name: Alejandro Moreno Title: Executive Vice President

ACCESS INDUSTRIES HOLDINGS (BVI) L.P. By: Access Industries Management, LLC, its General Partner

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

ACCESS INDUSTRIES, LLC By: Access Industries Management, LLC, its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

ACCESS INDUSTRIES MANAGEMENT, LLC /s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

*

Name: Len Blavatnik

By: /s/ Alejandro Moreno

Name: Alejandro Moreno Attorney-in-Fact

^{*} The undersigned, by signing his name hereto, executes this Schedule 13D pursuant to the Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.